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This positron emission tomography (PET) study aimed to further define selectivity of [
11C]Ro15-4513
binding to the GABARa5 relative to the GABARa1 benzodiazepine receptor subtype. The impact of
zolpidem, a GABARa1-selective agonist, on [
11C]Ro15-4513, which shows selectivity for GABARa5,
and the nonselective benzodiazepine ligand [
11C]flumazenil binding was assessed in humans.
Compartmental modelling of the kinetics of [
11C]Ro15-4513 time-activity curves was used to
describe distribution volume (VT) differences in regions populated by different GABA receptor
subtypes. Those with low a5 were best fitted by one-tissue compartment models; and those with
high a5 required a more complex model. The heterogeneity between brain regions suggested
spectral analysis as a more appropriate method to quantify binding as it does not a priori specify
compartments. Spectral analysis revealed that zolpidem caused a significant VT decrease (B10%) in
[
11C]flumazenil, but no decrease in [
11C]Ro15-4513 binding. Further analysis of [
11C]Ro15-4513
kinetics revealed additional frequency components present in regions containing both a1 and a5
subtypes compared with those containing only a1. Zolpidem reduced one component (mean±s.d.:
71%±41%), presumed to reflect a1-subtype binding, but not another (13%±22%), presumed to
reflect a5. The proposed method for [
11C]Ro15-4513 analysis may allow more accurate selective
binding assays and estimation of drug occupancy for other nonselective ligands.
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Introduction
Imaging studies of benzodiazepine receptors over the
past 20 years have revealed different levels of
binding in patients with anxiety and panic disorders,
alcoholism, schizophrenia, epilepsy, and other dis-
orders (Malizia et al, 1998; Lingford-Hughes et al,
2010; Busatto et al, 1997; Hammers et al, 2001).
There is increasing knowledge about the six different
subtypes of the GABA-benzodiazepine receptor, their
locations in the brain, and their functional implica-
tions. For instance, knock-in and knockout genetic
manipulations in mice have shown that the GABA-
benzodiazepine receptor subtype containing the a1
subtype is important in sedation and sleep, the a2/3
subtype is involved in anxiety, and the a5 in learning
and memory (Mo ¨hler et al, 2002). In the light of
these discoveries, it is important to study the role of
these receptor subtypes in humans. Neuroimaging,
in particular positron emission tomography (PET)
and single-photon emission tomography (SPET)
imaging with receptor-selective ligands, remains
the only way of quantifying benzodiazepine recep-
tors in the human brain in vivo.
[
11C]flumazenil with PET is the most commonly
used in vivo marker of benzodiazepine receptor
binding and its iodinated analogue, [
123I]iomazenil,
can be used with SPET. Flumazenil is an antagonist
that binds with high affinity to benzodiazepine
receptors of the a1, a2, a3, or a5( K iB1nmol/L)
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subtypes (Ki B150nmol/L (Sieghart, 1995)). Until
recently, there was no way of preferentially visualis-
ing particular subtypes. Ro15-4513 shows 10- to 15-
fold selectivity for the a5 subtype over others in vitro
(Ki 0.07nmol/L versus 1 to 5nmol/L), and in vivo
[
11C]Ro15-4513 PET provides a relatively selective
marker for the GABARa5 subtype (Hadingham et al,
1993; Lingford-Hughes et al, 2002; Maeda et al,
2003). These studies, among others, show that in vivo
[
11C]Ro15-4513 uptake targets the limbic system,
with the anterior cingulate cortex, ventral striatum,
and hippocampus showing particularly high levels
(Onoe et al, 1996), whereas high [
11C]flumazenil
binding is seen in all cortical areas, with highest
levels in the occipital cortex. Therefore, the limbic
pattern of [
11C]Ro15-4513 binding is likely to be
relevant to learning, memory, reward, and addiction.
For example, we have shown that an inverse agonist
at the a5 subtype can reverse the memory-impairing
effects of acute alcohol consumption (Nutt et al,
2007), and [
11C]Ro15-4513 binding is related to
performance on a verbal memory task in alcohol
dependence (Lingford-Hughes et al, 2010). The a5
subtype has also been implicated in the reinforc-
ing effects of alcohol in mice (Stephens et al, 2005),
and we have shown a reduction in [
11C]Ro15-4513
binding in the nucleus accumbens in alcohol depen-
dence compared with healthy controls (Lingford-
Hughes et al, 2010).
Although the distribution of [
11C]Ro15-4513 bind-
ing is consistent with relatively greater labelling of
the a5 subtype, the affinity of [
11C]Ro15-4513 is only
an order of magnitude greater for the a5 over other
subtypes. Given the abundance of the a1 subtype
throughout the brain, it is important to assess the
contribution of a1 binding to [
11C]Ro15-4513 bind-
ing. This study compares the binding of [
11C]Ro15-
4513 with that of [
11C]flumazenil in the presence and
absence of zolpidem, a compound with selectivity
for the a1 receptor subtype that is >5,000-fold over
that for the a5 subtype (Hanson et al, 2008; Langer
et al, 1992). Unlike classical benzodiazepines, the
sedative/hypnotic effect of zolpidem occurs at
much lower doses than the other pharmacological
effects attributed to benzodiazepine-site action, such
as anticonvulsant activity and muscle relaxation
(Sanger, 2004).
After predosing with zolpidem or placebo,
one group of healthy volunteers was scanned with
[
11C]Ro15-4513 and another group with [
11C]fluma-
zenil. Our hypothesis was that, because [
11C]fluma-
zenil labels the a1 subtype, its binding would
be reduced by zolpidem. In contrast, we hypo-
thesised that [
11C]Ro15-4513 binding would not be
altered by zolpidem in a5-rich regions such as
the hippocampus, whereas in a1-rich regions with
limited or no a5, such as the cerebral cortex
and thalamus, [
11C]Ro15-4513 binding might be
reduced. To further resolve contributions of a1 and
a5 subtypes to the [
11C]Ro15-4513 signal, we applied
spectral analysis (Cunningham and Jones, 1993) to
both [
11C]Ro15-4513 and [
11C]flumazenil data sets to
deduce the spectral band of the GABA-benzodiaze-
pine a1 subtype. The range obtained was used
to determine the occupancy by zolpidem of the
GABA a1 subtype from the [
11C]Ro15-4513 data using
the Lassen plot (Lassen et al, 1995; Cunningham
et al, 2010).
Materials and methods
This study was approved by a NHS Research Ethics
Committee, the Administration of Radioactive Substances
Advisory Committee and local NHS Research and Devel-
opment. It was conducted in accordance with Good
Clinical Practice—International Conference on Harmonisa-
tion guidelines.
Design
There were two separate randomised double-blind placebo-
controlled studies, each with six healthy volunteer parti-
cipants. The study procedures were identical apart from
the PET ligand used: [
11C]flumazenil for one study and
[
11C]Ro15-4513 for the other. Positron emission tomo-
graphy scans were performed twice for each participant,
once after zolpidem and once after placebo, with at least a
week between scans. Binding of the ligand was compared
between the two conditions.
Subjects
Healthy male volunteers (age mean±s.d.: [
11C]Ro15-4513:
44±6 years; [
11C]flumazenil: 43±4 years) underwent 2
PET scans at least a week apart, after zolpidem or placebo,
the order of which was randomised. They were all
screened with urinalysis for illicit drugs of abuse, had no
current or previous significant physical or mental dis-
orders, had taken no psychotropic drugs in the last month,
nor were regular benzodiazepine users.
Zolpidem and Measures
Zolpidem (20mg) or an identical placebo was administered
90minutes before radioligand injection and at the start of
the PETscan. Plasma zolpidem levels were measured at the
time of PET ligand injection.
The following tasks provided a measure of the effect
of zolpidem on brain function. Saccadic eye movements
to a target were measured using electrooculography as
described previously (Lingford-Hughes et al, 2005). The
subject was asked to fixate on a red light as it appeared
on the screen mounted 67cm in front of him. Data were
then collected for 48 eye movements of 151 to 401 and a
main sequence curve obtained, the measurement for peak
velocity being the interpolation at 351. Verbal memory was
tested with learning and delayed recall of a list of 20 words
(Nutt et al, 2007), with the list presented at the start of the
scan and recall 30minutes later.
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[
11C]Ro15-4513 was synthesised by N-methylation of the
N-desmethyl derivative with [
11C]iodomethane. Reverse-
phase high-performance liquid chromatography was used
to purify the compound (Phenomenex Ultra-carb 7 ODS,
250 10mm
2). [
11C]flumazenil was synthesised by methyla-
tion of the nor-derivative with
11CH3I.
A bolus injection of [
11C]flumazenil (mean±s.d.:
476±11MBq in 1.0±0.16mL) or [
11C]Ro15-4513
(mean±s.d.: 495±18MBq in 3.3±0.49mL) was adminis-
tered through an intravenous cannula sited in the domi-
nant antecubital fossa vein. No significant differences in
cold mass injected, with paired t-tests, between placebo
and zolpidem scans were found using either flumazenil
(mean±s.d.: 1.37±0.52mg to 1.09±0.28mg, t=1.28,
P>0.25) or [
11C]Ro15-4513 (mean±s.d.: 3.22±0.86mgt o
4.30±3.71mg, t=0.579, P>0.5).
We used a Siemens ECAT EXACT HR+ (CTI/Siemens,
model 962; Knoxville, TN, USA) scanner with an axial
field of view of 15.5cm. Subjects were positioned such that
the transaxial images were parallel to the intercommissural
line. A total of 63 transaxial image planes were acquired
as 2.42-mm slices with a reconstructed axial resolution
of 5.4mm and a transaxial resolution of 5.6mm (Spinks
et al, 2000). A 10-minute transmission scan was acquired
before every emission using a single rotating photon
point source of
137Cs for subsequent attenuation and scatter
correction.
[
11C]Ro15-4513 scans comprised 24 dynamic time frames
(1 30, 4 15, 4 60, 2 150, 10 300, 3 600seconds)
and [
11C]flumazenil scans comprised 20 time frames (1 30,
4 15, 4 60, 2 150, 2 300, 7 600seconds) of data
which, after corrections for attenuation, random coinci-
dences, and scatter, were all reconstructed using filtered
backprojection. The three-dimensional emission data were
Fourier-rebinned (Defrise et al, 1997) into two-dimensional
data sets to increase the speed of reconstruction.
Each subject had a radial arterial cannula inserted in the
nondominant wrist to allow continuous counting of blood
radioactivity concentration for the first 15minutes of the
experiment using a bismuth germanate counter. Discrete
samples were also taken 4, 6, 8, 10, 20, 35, 50, 65, 80, and
90minutes after injection. An aliquot of each discrete
sample was rapidly centrifuged to obtain corresponding
plasma and radioactivity concentrations. The continuous
blood counts were corrected using the estimated plasma/
blood ratio to derive the plasma radioactivity profile. The
plasma was further analysed for radiolabelled metabolites
using a semiautomated analysis system, consisting of an
on-line solid-phase sample enrichment column and high-
performance liquid chromatography. The amount of
[
11C]Ro15-4513 or [
11C]flumazenil in the plasma at a given
time point was calculated as a percentage of all radioactive
components separated by high-performance liquid chro-
matography added to the radioactivity present in the solid-
phase extraction fraction, to produce a final plasma input
function derived for radioligand-binding quantification.
These calculations were carried out using Clickfit, in-
house software running in Matlab (The Mathworks, Natick,
MA, USA).
All subjects had T1-weighted magnetic resonance imag-
ing with a Philips 1.5-T Gyroscan Intera scanner (Philips,
Best, The Netherlands) to produce structural images for
reference.
Image and Blood Analysis
Reconstructed PET images were analysed on a Sun
SPARC workstation (Sun Microsystems, Mountain View,
CA, USA) using Analyze AVW version 8.1 (Biomedical
Imaging Resource, Mayo Clinic, Rochester, MN, USA),
Matlab 6 and 6.5 (The Mathworks), and SPM5 (available
through http://www.fil.ion.ucl.ac.uk/spm/; FIL, 12 Queen
Square, London, UK).
Regions of interest were placed on the images using a
probabilistic map which defined 83 regions (Hammers
et al, 2007). A list of these regions is given in Appendix 1.
Each structural magnetic resonance image was coregistered
to the PET add image, a sum of all counts acquired during
the scan, using a rigid-body technique. This coregistered
magnetic resonance imaging was then normalised to the
‘Montreal Neurological Institute’ space (International
Consortium for Brain Mapping (ICBM)/MNI) using a
bias-corrected segmentation in SPM5. Using the reverse
parameters of this normalisation, the probabilistic map
could be warped to fit the coregistered structural magnetic
resonance imaging and hence the add image and the original
PET dynamic. The goodness of fit of each object map to the
individual brain was checked visually before regional
sampling using the region of interest tool in Analyze 8.1.
From the probabilistic map, we identified regions with
wide differences in a1a n da5 distribution: the cerebellum,
occipital cortex, and thalamus, which contain high a1l e v e l s
and very low a5 levels, and limbic regions such as the
hippocampus, nucleus accumbens, amygdala, and anterior
cingulate cortex with high a5 levels and lower a1l e v e l s
(Fritschy and Mo ¨hler, 1995; Lingford-Hughes et al,2 0 0 2 ) .
Modelling
Parametric maps of total volume of distribution (VT) were
created for both [
11C]Ro15-4513 and [
11C]flumazenil images
using receptor parametric mapping software written in
Matlab (RPM, MRCCU (Cunningham and Jones, 1993)).
Values for mean VT per voxel in each region of interest and
in combined regions were then sampled in Analyze 8.1, to
compare in vivo binding with and without zolpidem, for
the two different PET ligands.
The regional kinetics of uptake of [
11C]Ro15-4513 only
were computed from brain and plasma time-activity curves
(TACs) using one-tissue and two-tissue compartment
models, using Clickfit. Having estimated the delay, the
models used fixed blood volume (Vb) of 0.06, calculated
after a preliminary analysis of variable Vb and averaged
over 83 regions of interest. Goodness of fit for each model
in every region was represented using Akaike information
criteria. VT of [
11C]Ro15-4513 was then calculated from
the estimation of kinetic parameters in the two models
using the following equations: one-tissue compartment
VT=K1/k2; two-tissue compartment VT ¼ K1
k2 1 þ k3
k4
  
.
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To further elucidate the pharmacokinetics of [
11C]Ro15-
4513, Clickfit was again used to carry out spectral analysis
of each regional TAC collected from the original PET
dynamics. Spectral analysis (Cunningham and Jones, 1993;
Turkheimer et al, 1994) convolves the arterially derived
metabolite-corrected plasma input function with a first-
order poly-exponential, without specifying the number of
tissue compartments, to fit the TAC for any region, under
the assumptions of system linearity and time invariance.
The impulse response function (IRF) is described as
IRFðtÞ¼
P
i aiebit, where a and b are real, nonnegative
numbers. Overall, 100 discrete values of b on a logarithmic
scale (Turkheimer et al, 1994), corresponding to 100
different basis functions, were chosen, between 0.000631
to 1.0seconds
 1, a lower limit shown to show the greatest
interclass correlation coefficient (Barros et al, 2010). The
‘spectrum’ of peaks with height a, can be used to infer
pharmacological characteristics of the ligand and its
binding properties. Given that the area under the IRF
function is the total volume of distribution, the position
and height of spectral peaks can be used to estimate VT
using VT ¼
Pn
k¼i ðak=bk   lÞ, where n is the total number of
peaks, ak the kth peak height, bk is kth peak position, and l
the decay constant.
In the case of two specific binding sites, the total volume
of distribution VTcan be written as VT=VS1+VS2+VND, the
sum of the specific distribution volumes, VS1 and VS2, and
the nondisplaceable distribution volume VND. Particularly,
for [
11C]Ro15-4513, the VS1 relative to the specific binding
to GABARa5 and VS2 relative to the specific binding to
GABARa1 may be determined comparing the contribution
of different kinetics to the IRF in a5-rich regions with those
in region with little or no a5 density, before and after
blocking of the a1-binding signal by zolpidem. As the IRF
is linear, VS may be estimated for particular regions of the
spectrum, VS ¼
Pj
k¼i ðak=bk   lÞ, where i and j are integers,
j>i, representing b-values defined by pharmacological and
regional inference. The ranges of b chosen to estimate VS
for different subtypes are described in detail in the
‘Results’ section. All peaks with b>0.001seconds
 1 were,
attributed to their fast curve shape, assumed to represent
blood volume and nonspecific binding, and were therefore
excluded with a low-pass filter. A similar band-pass
approach to spectral analysis, based on regionally in-
formed frequency allocation, has been used to investigate
cerebral protein synthesis using L-[1-
11C]leucine PET by
Veronese et al, (2010).
Occupancy Plots
Occupancy data were derived graphically, as described by
Lassen et al (1995) (Cunningham et al, 2010), using the
vectors of the regional volumes of distribution in baseline,
VT
b, and postdrug, VT
d, as follows: VT
b VT
d =O
d (VT
b VND),
assuming that the VND and O
d, the receptor occupancy of
the blocking drug, were constant across brain regions.
If the imaging ligand has two binding sites and the
blocking drug is selective for only one of these binding
sites, VT
b and VT
d may be written as follows:
Vb
T ¼Vb
S1 þ Vb
S2 þ VND
Vd
T ¼Vd
S1 þ Vd
S2 þ VND ¼ Vb
S1 þ Vb
S2ð1   O
dÞþVND
ð1Þ
Therefore, we can draw two plots for the fractional
volumes of distribution defined above:
Vb
S1   Vd
S1 ¼ 0
Vb
S2   Vd
S2 ¼ O
dVb
S2
ð2Þ
The specific volume of distribution of [
11C]Ro15-4513
relative to each subtype was derived using spectral analysis
with the assumption that a given spectral range corre-
sponded to binding to a single site. In addition, we made the
further assumption that, although the blocking drug will
change the positions of the spectral peaks, the volume of
distribution of the imaging ligand relative to the binding to
the site not targeted by the cold drug will be the same in the
baseline and postdrug PET studies. Both assumptions were
tested using zolpidem blocking data, as reported in the
‘Results’ section. The 83 region atlas (Appendix 1) provided
a large number of regional volumes of distributions for use
in the plots. The gradient of a linear regression through the
points on the axes, x=(VS
b), y=(VS
b VS
d), estimated the
zolpidem occupancy O
d at the given receptor subtype.
Statistical Analysis
Two-tailed Student’s t-statistic was used to interrogate
demographic variables, zolpidem levels, as well as objec-
tive and subjective measures between the two scanning
groups and within groups in the presence and absence of
zolpidem. Mean VT estimates for the whole brain with
and without zolpidem were also compared with Student’s
t-test, whereas the effect of zolpidem on binding in
selected regions (such as the whole brain, occipital cortex,
cerebellum, hippocampus, nucleus accumbens, frontal
lobe, anterior cingulate, amygdala), was interrogated with
two-way analysis of variance (ANOVA). Two-way repeated-
measures ANOVA with P-plot graphical test and the
Hochberg multiple comparison correction (Turkheimer
et al, 2001) across all 83 regions was used to compare
[
11C]Ro15-4513 and [
11C]flumazenil VT, with and without
zolpidem. One-way ANOVA was used to compare the
estimated parameters of the different compartmental
models, with pairwise comparisons conducted using
Tukey’s post hoc tests. To test the significance of the line
through the regional VT estimates in occupancy plots,
linear regressions were used. All statistical analyses were
conducted using GraphPad Prism (version 4.02 for Win-
dows, GraphPad Software, San Diego, CA, USA, http://
www.graphpad.com).
Results
One [
11C]Ro15-4513 pair of scans was not analysable
after a subject dropped out of the study, so we report
here the remaining five. There was no significant
difference in zolpidem levels in the two groups,
although only three blood samples were successfully
acquired in the [
11C]Ro15-4513 cohort (mean±s.d.:
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11C]Ro15-4513 n=3: 107.9±33.1ng/mL; [
11C]fluma-
zenil n=6: 84.9±41.1ng/mL; t=0.84; P>0.40).
These levels are consistent with those reported in
the literature (Salva ` and Costa, 1995). Zolpidem
resulted in impaired saccadic eye movements: peak
velocity at 90minutes postingestion was 11.9% after
placebo and 38.1% after zolpidem (t=3.75;
P<0.005); the percentage of failed saccades was
20.3% after placebo and 59.4% after zolpidem
(t=4.60; P<0.0005). Zolpidem also impaired learn-
ing and delayed recall of the 20-word list similarly in
both groups. In the [
11C]Ro15-4513 group, the
number of words recalled reduced from 6.8±4.2 to
3.4±4.0 and in the [
11C]flumazenil group from
9.2±5.1 to 2.2±1.7.
Compartmental Modelling of [
11C]Ro15-4513
Compartmental modelling was applied to all
[
11C]Ro15-4513 regional data, estimating kinetic
parameters and goodness of fit, represented by the
Akaike information criteria. All data for the placebo
group are shown in Table 1, presented as mean±s.d.
for both models. All rate constants are expressed as
seconds
 1.
Using a one-tissue compartment model with fixed Vb
(2kbvf), estimates of K1a n dk2 were consistently small
and positive, through all regions and all individuals
(K1=0.0050±0.0011; k2=0.0015±0.0008). Vb was
fixed at 0.06, calculated as the average of estimated
Vb in all 83 regions.
The two-tissue compartment model (4kbvf), yielded,
on average, higher estimates for K1a n dk2t h a nd i dt h e
one-tissue compartment model, but very low values
for both k3a n dk4, expressed as seconds
 1 (4kbvf
results: K1=0.0053±0.0001; k2=0.0019±0.0001;
k3=0.00042±0.00443; k4=0.00050±0.00731). These
differences were statistically significant applying a
one-way ANOVA for each model parameter. Mean
estimations of K1a n dk2 from the four different models
were significantly different (K1: F=13.71; P<0.0005,
k2: F=12.49; P<0.0005), and Tukey’s post hoc tests
showed significance for both K1a n dk2( P<0.01)inall
comparisons of one- to two-tissue models.
Kinetic modelling of TACs from regions rich in
GABARa1 receptors gave differing results compared
with regions rich in GABARa5 receptors. In the
GABARa1-rich cerebellum, the one-tissue compart-
ment model fitted TACs almost as well as did the
two-tissue compartment model (Akaike information
criteria better in 3 of 5 individuals, average 6.8%
more negative), but the two-tissue model produced
consistently very small negative estimates of either
or both k3 and k4. However, in the GABARa5-rich
hippocampus, there was a significantly better fit
using the two-tissue model compared with the one-
tissue model (Akaike information criteria better in all
individuals, average 46.9% more negative) and
estimates of BP (calculated using k3/k4) that were
positive and small.
Although the estimates of rate constants differed
significantly, as did the fits of the curves, similar
overall VTs were obtained with each model, and both
models showed the same pattern of variability
between individuals.
Spectral Analysis
[
11C]Ro15-4513: As previously reported, the highest
[
11C]Ro15-4513 VTs were seen in limbic regions such
as the nucleus accumbens and hippocampus (see
Figure 1A; Lingford-Hughes et al (2002, 2010)). All
results are presented as mean±s.d. There was no
reduction in [
11C]Ro15-4513 VT in the presence of
zolpidem in the whole brain (postplacebo:
3.69±0.22; postzolpidem: 3.81±0.47) nor among
the combined regions (F=0.0107; P>0.90; see
Figure 1B). Sampling all of the 83 regions from the
probabilistic map, a repeated-measures ANOVA
showed a marginally significant increase in VT
(F=4.363; P<0.05) after zolpidem. There was some
variation between individuals (see Figure 1), with
zolpidem causing a reduction in binding in one
subject.
[
11C]Flumazenil: For [
11C]flumazenil binding, a signi-
ficant effect of zolpidem was observed. Throughout
the whole brain, VTwas B10% lower in the presence
of zolpidem (VT postplacebo: 4.10±0.56; postzolpi-
dem: 3.70±0.37; F=14.57; P<0.0005; see Figure 2).
The effect remained significant when all 83 regions
were sampled (F=123.7; P<0.0001). No individual
region survived correction for multiple comparisons.
Zolpidem reduced [
11C]flumazenil VT in four of the
six volunteers (see Figure 2B).
Spectral Analysis: Assessment of Spectral Peaks
The distribution of spectral peaks in different regions
was identified using Clickfit. Each region yielded a
Table 1 Comparison of the kinetic rate constants obtained
using different compartmental models to determine Ro15-4513
binding in the brain
K1 k2 k3 k4 AIC
All regions
2kbvf 5.0±1.1 1.5±0.8 — —  89.09±27.8
4kbvf 5.4±1.1 1.9±1.2 0.42±4.43 0.50±7.31  100.76±28.8
Cerebellum
2kbvf 6.0±0.7 3.1±0.4 — —  126.43±18.1
4kbvf NA NA NA NA NA
Hippocampus
2kbvf 4.3±0.4 0.77±0.13 — —  63.46±13.6
4kbvf 5.2±0.5 1.6±0.5 0.75±0.56 0.48±0.81  93.79±15.6
AIC, Akaike information criteria; NA, not available.
All constants are expressed as mean±s.d. secconds 10
 3. Binding in the
cerebellum was not successfully evaluated by a two-tissue compartment model.
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representing one of 100 values of b, described in
the ‘Materials and methods’ section. These results
were pooled and a summed peak height for each
peak was calculated for each region and each PET
tracer in the presence or absence of zolpidem. The
average height for each b-value was not representa-
tive of the true peak distribution, because the peaks
are discrete and the spectral analysis algorithms
assign consecutive values for those peaks not
matching a predefined b.
There was a clear average peak height decrease
with zolpidem for both ligands. For [
11C]Ro15-4513,
the differences were seen between 0.0020
and 0.0030seconds
 1. With [
11C]flumazenil, the
decreases were seen at faster rates, between 0.0030
and 0.0050seconds
 1 (data not shown).
To further investigate the source of these differ-
ences, a smaller number of brain regions with high
and low a1 levels were selected for further analysis.
Figures 3 and 4 illustrate data for the cerebellum and
hippocampus after [
11C]Ro15-4513 and [
11C]flumaze-
nil, respectively. As zolpidem is a GABARa1 agonist,
it was expected that regions with high a1 levels and
low levels of other GABA receptor subtypes should
show a greater change in peak profile than areas with
lower a1 levels. In the cerebellum, a region with
almost solely high a1 levels, the fast kinetic profile
for [
11C]Ro15-4513 without zolpidem represents a1
subtype binding (average height=0.00306seconds
 1;
range of peaks 0.0030 to 0.0040seconds
 1, see Figure
3A). Zolpidem reduced average [
11C]Ro15-4513 peak
height, lessening the contribution of those curves to
the IRF and spreading their range (average
height=0.00185seconds
 1; range of peaks 0.0020 to
0.0060seconds
 1, Figure 3A). The effect of zolpidem
was estimated for this band of peaks in the
cerebellum, to assess proposed a1 blockade. There
was a significant decrease in VS after zolpidem
(3.99±0.31 to 3.41±0.22, t=2.827; P<0.05).
In contrast, in the hippocampus, a region with high
a5 levels but also containing the a1 subtype, there are
two clear ranges of kinetic components of [
11C]Ro15-
4513 (see Figure 3B). The fast component in the
placebo scan (average height=0.00122seconds
 1;
range of peaks 0.0025 to 0.0045seconds
 1) is reduced
and broadened in the presence of zolpidem (average
height=0.00065seconds
 1; range of peaks 0.0020 to
0.0060seconds
 1). This reduction in VS is significant
(1.40±0.92 to 0.44±0.60, t=2.369; P<0.05) and
analogous to that found in the cerebellum, suggesting
that this peak range reflected the a1 subtype. In the
hippocampus, there was also a slower component,
unaffected by zolpidem (11.51±3.44 to 10.00±2.59,
t=0.8291; P>0.45), which contributed to the majority
of the convolution after zolpidem administration
(placebo: average height=0.00179seconds
 1; range
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Figure 1 [
11C]Ro15-4513 scans. (A) Estimates of mean
[
11C]Ro15-4513 VT in different ROIs with and without zolpidem.
Error bars show s.e.m. of the five volunteers. (B) Intersubject
variability, for the five volunteers, in [
11C]Ro15-4513 VT
estimation in the whole brain. These data represent
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Figure 2 [
11C]Flumazenil scans. (A) Estimates of mean fluma-
zenil VT in different ROIs with and without zolpidem. Error bars
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observable decrease in binding with zolpidem administration,
although significance did not survive post hoc correction.
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 1; zolpidem:
average height=0.00177seconds
 1; range of peaks
0.0010 to 0.0016seconds
 1, Figure 3B).
Comparable results for spectral analysis of [
11C]flu-
mazenil in the cerebellum and hippocampus are
shown in Figure 4. Although there are no clear
distinctions between fast and slow kinetic compo-
nents, there are differences in estimates of VT. For
peaks between 10 and 50, there is a consistent and
trend-level decrease in binding after zolpidem
administration in the cerebellum (6.11±1.18 to
5.16±0.42, t=3.343; P<0.06), and significant in
the hippocampus (7.78±0.98 to 6.40±1.37,
t=2.923; P<0.05). The homogeneity of the spectra
precluded any further separation of peaks based on
regional receptor densities.
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Figure 3 Comparison of [
11C]Ro15-4513 spectral analysis results in (A) the cerebellum and (B) hippocampus, with data summed
over five subjects. Only peaks 1 to 50 (frequency range 0.000631 to 0.00873 seconds
 1) are shown.
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Figure 4 Comparison of [
11C]flumazenil spectral analysis results in (A) the cerebellum and (B) hippocampus with data summed over
five subjects. Only peaks 1 to 50 (frequency range 0.000631 to 0.00873 seconds
 1) are shown.
GABARa1 contribution to [
11C]Ro15-4513 PET images
JFM Myers et al
737
Journal of Cerebral Blood Flow & Metabolism (2012) 32, 731–744Occupancy Estimation
The lack of effect on average VS by zolpidem in the
‘slower’ end of the spectrum, and the decrease in the
‘faster’ range, led to broad estimates of i and j that
would include all peaks in the two ranges. VS values
were calculated for both slow range (i=1;j=25) and
fast (i=25; j=50), with and without zolpidem. (VS
b)
was plotted against (VS
b VS
d) to produce occupancy
plots, shown in Figure 5. For the slow range, little or
no occupancy was shown, as expected because this
was assumed to represent binding to the a5 subtype
(Figure 5A). Two of the five regression plots were
significantly different from zero, but with values of
occupancy <20%, one positive and one negative.
For the fast range, representing the a1 subtype, there
are positive estimates of occupancy between 42.9
and 84.8% (mean±s.d.: 64.3%±15.2%), with linear
regression significantly different from 0 consistently
with P<0.0001 (Figure 5B).
Occupancy was also estimated using plots for each
of the six volunteers in the [
11C]flumazenil cohort.
The results are shown in Figure 6. VTwas calculated
by voxel-wise spectral analysis described earlier.
Only 2 volunteers showed data fitted significantly by
regression, giving zolpidem occupancy estimates of
30 and 33%.
Discussion
We have shown that zolpidem significantly reduced
[
11C]flumazenil VT in the whole brain by B10%,
whereas there is no reduction in [
11C]Ro15-4513 VT.
These results suggest that the GABARa1 binding of
[
11C]Ro15-4513 does not significantly affect overall
VT, whether estimated by spectral analysis to pro-
duce parametric maps of VT, or by compartmental
modelling. However when frequency components of
spectra derived from [
11C]Ro15-4513 images, pro-
posed to reflect binding to the a1 subtype, are used to
estimate VS, occupancy by zolpidem is shown to
range from 43% to 85%. The dose of zolpidem was
shown to be clinically relevant as it induced sedation
and significantly impaired saccadic eye movement
performance and word list recall.
The difference in binding properties of nonselec-
tive ligands in regions with differing populations
of receptor subtypes ought to be demonstrable by
applying various compartmental models. We hypo-
thesised that more complex models would be
required where there are multiple subtypes com-
pared with brain regions with predominantly one
subtype. One- and two-tissue compartmental models
showed similar variability between individuals,
but a different quality of fit to the data depending
on region. In the cerebellum, an a1-rich region, one-
tissue compartment models provided the best fit for
observed data, with higher K1 and k2. Pharmacologi-
cally, this corresponds to the rapid kinetic profile
expected from the fast binding of a benzodiazepine
ligand with relatively low affinity to the cerebellar
subtypes. By contrast, in the hippocampus, the
two-tissue compartment model was superior to the
one-tissue compartment model. In addition, lower
estimates of k2 suggested a slower kinetic profile to
that in the cerebellum. We suggest that this slower
kinetic profile represents high-affinity binding to the
GABARa5 subtype in a5-rich regions. These results
are consistent with those of Maeda et al (2003) in
nonhuman primates, who also showed that there are
different kinetic components in regions containing
different subtype levels and ratios.
Both [
11C]flumazenil and [
11C]Ro15-4513 bind to
more than one GABA a receptor subtype. Flumazenil
binds with similar affinity (B1nmol/L) to a1, a2, a3,
and a5 GABA-benzodiazepine receptors and lower
affinity at a4 and a6 subtypes (Sieghart, 1995). Ro15-
4513 has 10- to 15-fold higher affinity for the a5
subtype (0.7nmol/L) compared with all remaining
subtypes (Hadingham et al, 1993). Conventional
compartmental modelling does not, in practical
terms, accurately describe the complex pharmaco-
dynamics when multiple receptor subtypes are
present, especially when the different subtypes
behave differently kinetically and are present in
varying ratios depending on the brain region. In this
study, compartmental modelling of [
11C]Ro15-4513
was not sensitive enough to detect changes in lower-
affinity binding to a1 the subtype. Despite the
usefulness of these models to show different regional
kinetics, they are pharmacological simplifications
and not suitable for accurately describing nonselec-
tive ligands in quantitative analyses, although a
two-tissue compartment model was proposed as
effective in all regions by Asai et al (2009). Given
that no one-compartmental model adequately repre-
sented the kinetics of tracer binding in all tissues,
and that there are multiple specific binding sites, we
suggest this imposes limitations on using the
reference region approach for a5-rich regions because
it violates its underlying principle that the volume of
distribution of nontarget bound ligand is the same in
target and reference tissues (Lammertsma and Hume,
1996). The pons is often used as a reference region,
given the lack of suitable region devoid of benzodia-
zepine receptors, but the low binding in the pons is
not sufficient to fully meet the assumptions of the
reference tissue model. Therefore, binding in regions
of interest is underestimated and/or additional steps
have to be taken to more accurately estimate such
specific binding levels (Litton et al, 1994; Klumpers
et al, 2008; Asai et al, 2009).
In this study, spectral analysis consistently yielded
higher estimates of VT relative to compartmental
modelling. The whole-brain spectral profiles, using
all 83 regions defined in the atlas (Appendix 1;
Hammers et al, 2007), showed that with both
[
11C]flumazenil and [
11C]Ro15-4513, zolpidem redu-
ced the height of peaks in certain frequency ranges.
Subtype differences could not be immediately
inferred from these spectral frequency components,
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Figure 5 Occupancy plots using the fractional volume of distribution in baseline and postdrug studies, according to equation (2),
are shown for each subject. (A) Occupancy plots using VS1, defined by the ‘slow’ peak of the spectral analysis results (summing
over 1rkr25). (B) Occupancy plots using VS2, defined by the ‘fast’ peak (summing over 25rkr50). Zolpidem occupancy
values obtained by linear regression, together with R
2, are shown in each plot. Each data point represents the volume of
distribution calculated for each ROI as listed in Appendix 1, excluding the ventricles, known to contain no GABA receptors. ROI,
region of interest.
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of subtype ratios in the large number of brain
regions included in the analysis. Unfortunately, the
spectrum for [
11C]flumazenil proved too homo-
geneous for separation of peaks based on regional
receptor subtype density. However, for [
11C]Ro15-
4513 images, in a5-rich regions such as the
hippocampus and nucleus accumbens, we found a
high-affinity binding site with a slower kinetic
profile, consistent with the fitting of data from these
regions with two-tissue compartment models. This
slow component was not affected by zolpidem
administration, and was therefore attributed to
high-affinity binding to the a5 subtype. In addition,
in both a5-rich and a5-poor regions, there was a
fast kinetic component present that was signifi-
cantly reduced after zolpidem administration, most
likely representing specific binding with lower
affinity to the a1 subtype. The intersubject variability
of specific volume of distribution defined using
these spectral bands was lower than for the total
volume of distribution, VT. Therefore, spectral
analysis was shown to be sensitive to detect the
contribution of lower-affinity binding of [
11C]Ro15-
4513 to GABARa1 in vivo.
Confirmation of these subtype-specific frequency
components in [
11C]Ro15-4513 images may be pro-
vided with further study using a5-specific blockade.
Until that is done, we cannot absolutely exclude that
a2a n da3 subtypes may have contributed to the
spectra we have taken to represent a5. In addition,
there are no drugs selective for a2 and/or a3
available. More broadly, these spectral band-pass
methods may be useful to further sharpen analytical
tools for in vivo PET assays, by reducing noise in the
spectrum and by allowing possible subtype-specific
probes into other nonselective ligands such as
[
11C]diprenorphine and [
11C]PHNO. Similarly, sub-
type-specific analyses of [
11C]Ro15-4513 PET in
clinical and pharmacological applications may yield
group effects hitherto overlooked because of the
influence of other subtypes on the binding.
Benzodiazepine agonists have previously been
believed to exert their effects when occupying only
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Figure 6 Occupancy plots for the [
11C]flumazenil cohort, showing VT calculated by voxel-wise spectral analysis in each region.
Zolpidem occupancy values obtained by linear regression, together with R
2 are shown in each plot. Each data point represents the
volume of distribution calculated for each ROI as listed in Appendix 1, excluding the ventricles, known to contain no GABA receptors.
ROI, region of interest.
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This is based on [
11C]flumazenil PET and [
123I]ioma-
zenil SPET studies showing sedation or sleep is
associated with clonazepam (0.03mg/kg) at 15% to
23% occupancy, with diazepam (30mg) at 24%, with
alprazolam (2mg) at 16%, and with midazolam
(50mcg/kg) at 17% to 35% or (6mg/h) at 20% to
30% (Shinotoh et al, 1989; Pauli et al, 1991;
Videbaek et al, 1993; Malizia et al, 1996; Fujita
et al, 1999). Zolpidem is the only licensed benzo-
diazepine subtype-selective drug with appropriate
pharmacokinetics we were able to give to humans
though, as it is an agonist, this limited the dose we
were able to give safely. Abadie et al (1996) reported
that 20mg oral zolpidem resulted in 20% to 29%
occupancy of benzodiazepine receptors assessed
with [
11C]flumazenil PET. We report that using
[
11C]flumazenil, although occupancy cannot be
directly estimated, the relatively small global
decreases of B10% in VT indicate this apparently
low occupancy was made more indeterminate by the
signal from receptor subtypes other than a1. Lassen
plots confirm that only two volunteers show signi-
ficant regressions, estimating occupancy of B30%
with VNS >1.5. However, when using the higher
frequency component of [
11C]Ro15-4513 to estimate
VS at only the presumed a1 site, occupancy estimates
ranged from 43% to 85%. This is accompanied by low
VNS estimates, <1 in most volunteers. What contri-
butes to this range is unclear. We are unable
to determine whether this was related to plasma
levels because only samples from three indivi-
duals were available and we only measured one time
point and so we have limited pharmacokinetic
information. Nevertheless, this higher occupancy is
more consistent with that estimated by calculating
that a 20mg tablet given to a 100kg individual will
result in plasma levels of 650nmol/L. Assuming a
volume of distribution in the brain of 0.5% and 90%
protein binding, B130nmol/L will be available in the
brain. As zolpidem has an affinity of B100nmol/L at
GABARa1( H a n s o net al, 2008; Hadingham et al,
1993), the administered level of zolpidem should
result in high occupancy at this subtype.
It was notable that for both PET ligands, there was
high intersubject variability of the effect of zolpidem
on ligand binding. This is consistent with report by
Abadie et al (1996) who also used 20mg zolpidem
with [
11C]flumazenil PET and described ‘spurious’
intersubject variability including increases in
[
11C]flumazenil binding in the presence of zolpidem
as we saw in some of our subjects. Therefore, it
seems that subject heterogeneity is commonly seen
when investigating the GABA system, of which one
consequence has been some studies require large
numbers of individuals. It is not clear what con-
tributes to the variability of [
11C]flumazenil and
[
11C]Ro15-4513 binding but because both ligands
bind to several different benzodiazepine subtypes,
it is possible that relatively small variations in rece-
ptor density ratios have a role. For instance, with
[
11C]Ro15-4513, the greater contribution to binding
potential is proposed to come from the high-affinity
GABARa5 component, which will be sensitive in
ratio to the ubiquitous GABARa1 component. Simi-
larly, it is possible that different subtypes are
differentially affected by changes in endogenous
GABA levels. It is for this reason that we have
developed this technique with [
11C]Ro15-4513 to
describe the contribution of benzodiazepine receptor
subtypes to this variability. This method results in an
importantly consistent spread of positive occupancy
estimations across all individuals.
We believe this development and application of
spectral band-pass methods will help characterise
benzodiazepine receptor subtypes as compounds
with appropriate relative affinities become available.
The use of nonselective ligands to show in vivo
occupancy of receptor-selective compounds will be
more accurate as specific binding of the ligand is
estimated. At present, [
11C]flumazenil PET has been
used to determine occupancy by two such com-
pounds, TPA023 at a2 and a3 and a5IA at a5 (Atack
et al, 2011). As [
11C]flumazenil is nonspecific and
a5IA and TPA023 each have equivalent affinity for
a1, a2, a3, and a5 subtypes, the reduction in
[
11C]flumazenil was presumed to reflect occupancy
equally at all subtypes to infer occupancy at a2/a3 for
TPA023 and a5 for a5IA. Eng et al (2010) emphasised
the importance of establishing the plasma-occupancy
relationship in humans rather than merely relying on
preclinical data because in both studies, the EC50 in
humans was lower compared with preclinical data.
Therefore, the approach we have adopted here will
greatly enhance our ability to understand the role of
different benzodiazepine subtypes and its potential
to determine contribution of receptor subtypes in
other nonspecific ligands.
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Appendix 1
Region List
(R=right, L=left)
R hippocampus
L hippocampus
R amygdala
L amygdala
R anterior temporal lobe—medial
L anterior temporal lobe—medial
R anterior temporal lobe—lateral
L anterior temporal lobe—lateral
R parahippocampal and ambient gyri
L parahippocampal and ambient gyri
R superior temporal gyrus
L superior temporal gyrus
R middle and inferior temporal gyri
L middle and inferior temporal gyri
R lateral occipitotemporal gyrus (fusiform gyrus)
L lateral occipitotemporal gyrus (fusiform gyrus)
R cerebellum
L cerebellum
Brainstem
L insula
R insula
L occipital lobe—lateral
R occipital lobe—lateral
L gyrus cinguli—anterior part
R gyrus cinguli—anterior part
L gyrus cinguli—posterior part
R gyrus cinguli—posterior part
L frontal lobe
R frontal lobe
L posterior temporal lobe
R posterior temporal lobe
L parietal lobe
R parietal lobe
L caudate nucleus
R caudate nucleus
L nucleus accumbens
R nucleus accumbens
L putamen
R putamen
L thalamus
R thalamus
L pallidum
R pallidum
Corpus callosum
R lateral ventricle—frontal horn, central part and occipital
horn
L lateral ventricle—frontal horn, central part and occipital horn
R lateral ventricle—temporal horn
L lateral ventricle—temporal horn
Third ventricle
L precenntral gyrus—frontal lobe
R precenntral gyrus—frontal lobe
L straight gyrus—frontal lobe
R straight gyrus—frontal lobe
L anterior orbital gyrus—frontal lobe
R anterior orbital gyrus—frontal lobe
L inferior frontal gyrus—frontal lobe
R inferior frontal gyrus—frontal lobe
L superior frontal gyrus—frontal lobe
R superior frontal gyrus—frontal lobe
L postcentral gyrus—parietal lobe
R postcentral gyrus—parietal lobe
L superior parietal gyrus—parietal lobe
R superior parietal gyrus—parietal lobe
L lingual gyrus—occipital lobe
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L cuneus—occipital lobe
R cuneus—occipital lobe
L medial orbital gyrus—frontal lobe
R medial orbital gyrus—frontal lobe
L lateral orbital gyrus—frontal lobe
R lateral orbital gyrus—frontal lobe
L posterior orbital gyrus—frontal lobe
R posterior orbital gyrus—frontal lobe
L substantia nigra
R substantia nigra
L subgenual frontal cortex
R subgenual frontal cortex
L subcallosal area
R subcallosal area
L presubgenual frontal cortex
R presubgenual frontal cortex
L superior temporal gyrus, anterior part
R superior temporal gyrus, anterior part
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